Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective

Francis CC Chow1*, Siew-Pheng Chan2, Chi-Min Hwu3, Sompongse Suwanwalaikorn4, Akira YT Wu5, Susan Yu Gan6, Manuel B Zacarias7

ABSTRACT

It is well recognised that Asia is at the epicenter of the global type 2 diabetes epidemic. Driven by socioeconomic changes involving industrialization, urbanization and adoption of Western lifestyles, the unprecedented increases in the prevalence of diabetes are particularly evident in Southeast Asia. The impact of diabetes is immense, and despite evidence of the benefit of optimal glucose control in reducing the risk of disease progression and development of macrovascular and microvascular complications, many individuals in this region remain poorly controlled. Chronic kidney disease (CKD) is an increasingly common diabetes-associated complication in Asian patients. Furthermore, Southeast Asia has one of the highest rates of end-stage renal disease (ESRD) in the world. Consequently, CKD in diabetes is associated with considerable morbidity and cardiovascular-related mortality, highlighting the need to screen and assess patients early in the course of the disease. The management of type 2 diabetes patients with declining renal function represents a significant challenge. Many of the older antidiabetic agents, such as metformin and sulfonylureas, are limited in their utility in CKD as a result of contraindications or hypoglycemic episodes. In contrast, dipeptidyl-peptidase IV inhibitors have provided a welcome addition to the therapeutic armamentarium for achieving glycemic control in these special populations. With comparable efficacy to and more favorable pharmacokinetic and side-effect profiles than traditional therapies, agents in this drug class, such as linagliptin, offer a more tailored approach to disease control in type 2 diabetes patients with declining renal function. (J Diabetes Invest doi: 10.1111/jdi.12006, 2012)

KEY WORDS: Chronic kidney disease, Dipeptidyl-peptidase IV inhibitors, Type 2 diabetes

CURRENT BURDEN OF TYPE 2 DIABETES IN SOUTHEAST ASIA

Type 2 diabetes continues to present a public health burden across the world, and Asia is considered to be at the epicenter of this diabetes epidemic, with 60% of the disease burden borne by this region1-3. The increase in diabetes prevalence across Asia has been rapid, fuelled by increasing obesity, aging populations and urbanization, which in turn have been driven by rapid economic development, a sedentary lifestyle and increased consumption of refined foods3. These socioeconomic changes have been particularly significant in countries across Southeast Asia4, and reflected by dramatic rises in type 2 diabetes prevalence over the past decade (Figure 1). Indeed, Indonesia and the Philippines are projected to be among the top 10 countries in the world with the highest number of estimated cases by 20305. Another issue curtailing the type 2 diabetes rise in Asia is the high number of undiagnosed individuals. For instance, in Hong Kong and Taiwan it was reported that almost 53% of diabetic patients remain undiagnosed5. Furthermore, the prevalence of pre-diabetes (impaired glucose tolerance) further adds to the already burgeoning burden of overt diabetes and its consequences in this region (Figure 1).

It is widely recognized that diabetes is a major source of morbidity, mortality and economic burden6. Prolonged and poor glucose control increases the risk of developing macrovascular (coronary artery disease, stroke) and microvascular (nephropathy, retinopathy and neuropathy) complications7, which can greatly reduce life expectancy and quality of life8. In fact, the risk of all-cause mortality (cardiovascular and non-cardiovascular) is
higher in diabetic than non-diabetic patients\(^9,10\). Consequently, the rapidly growing prevalence of diabetes in Asia is likely to result in large increases in diabetes-associated mortality\(^9\).

From an economic perspective, the impact of diabetes on healthcare resources and personal expenditure, as well as the financial implications associated with loss in productivity and disability, is enormous\(^1\). In Taiwan, the direct healthcare cost associated with diabetes was 11.5% of the total national healthcare cost and was 4.3-fold higher than the care of non-diabetic individuals\(^1\). In Hong Kong, the annual total cost of type 2 diabetes equated to USD 1,725 ± 2,044 per patient. These costs increased considerably if complications were present\(^4\). Furthermore, complications increased treatment costs associated with inpatient hospital stay by between 6 and 300% compared with treatment of type 2 diabetes patients without complications\(^4\). Of note is the considerable heterogeneity in healthcare spending for diabetes between countries across Southeast Asia. The International Diabetes Federation estimated that, in 2010, treatment of diabetes accounted for 5 and 7% of the total healthcare expenditure in Vietnam and Indonesia, respectively, compared with 15 and 16% in Singapore and Malaysia, respectively\(^1\). Taken together, it is clear that early diagnosis and disease control are important healthcare initiatives to improve the lives, outcomes and economies of these at-risk countries.

In determining the optimal management approach, recognizing the differences in clinical characteristics and risk of diabetes between Asian and Caucasian populations is important to understand. For instance in Asians, diabetes develops over a shorter time, in younger people and in those with a lower body mass index (BMI)\(^15\). Furthermore, Asians have a higher proportion of body fat and abdominal obesity, putting them at a higher risk of developing insulin resistance\(^16,17\). Reports that Asians show early \(\beta\)-cell dysfunction might further explain their increased susceptibility to type 2 diabetes\(^16,17\).

The thrifty gene and thrifty phenotype hypotheses have been proposed as plausible explanations for the increasing diabetes epidemic seen across Asia\(^18\). Although considered protective during periods of famine or food shortage, thrifty genes have rendered individuals highly predisposed to obesity in times of plenty. Alternatively, the thrifty phenotype relates to the impact of an unfavorable intrauterine environment (e.g. undernutrition) and low birth weight on the subsequent development of diabetes and metabolic syndrome in adults\(^18\).

Several diabetes-associated genes have been implicated to account for the heightened predilection in Asians, especially Asian Indians, and include polymorphisms of the peroxisome proliferator-activated receptor co-activator-1 alpha (PGC-1 alpha) gene, plasma cell glycoprotein (PC-1) gene and insulin receptor substrate (IRS-2) gene (reviewed in Radha and Mohan\(^19\)).

Given the increased prevalence of diabetes among younger populations in Asia and early exposure to hyperglycemia, it has been suggested that they are also at a high risk of end-organ damage and are likely to have to live with complications for longer\(^20\). Indeed, the Asia-Pacific Cohort Studies Collaboration (APCSC), which assessed the impact of diabetes on cardiovascular outcomes and mortality, found a greater risk of fatal coronary heart disease, hemorrhagic and ischemic stroke among younger compared with older individuals\(^21\). APCSC also showed an association between diabetes and increased risk of death as a result of renal disease, cancer, respiratory infections, and other infective and inflammatory causes\(^21\). Although optimal blood glucose control has been shown to reduce the risk of both macrovascular and microvascular complications\(^2\), the marked prevalence of renal dysfunction in Asia reflects, in part, the continuing challenge in achieving this goal\(^22\).

The aim of the present article was to review the barriers to achieving optimal blood glucose control in Asian patients with type 2 diabetes who have declining renal function and to discuss the treatment modalities that might be appropriate for the management of these special patient populations.

### DIABETES AND CHRONIC KIDNEY DISEASE COMPLICATIONS IN ASIA

Of the diabetes-associated complications, the most debilitating is chronic kidney disease (CKD) and its pathogenic progression to end-stage renal disease (ESRD) that requires dialysis or transplantation\(^23\). Defining and diagnosing CKD in clinical practice has evolved since its first classification by the National Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) in 2002\(^24\). In these guidelines, CKD was categorized into five stages according to the severity of disease as defined by decreasing glomerular filtration rates (GFR) alone\(^24\). In the more recent update, the assessment criteria have been modified to encompass both GFR and albuminuria measures as correlates of a patient’s prognosis. In addition, a subdivision of the previously described GFR stage 3 has been proposed to help further define the severity of kidney dysfunction in patients with CKD\(^25\).

Risk factors for the development of reduced kidney function in Southeast Asian populations have been identified and
include the presence of diabetes, systolic hypertension (>159 mmHg), hyperuricemia (>6.29 mg/dL), elevated BMI (>24.9 kg/m²) and hypercholesterolemia (>248.3 mg/dL)

Microalbuninuria and Type 2 Diabetes

Microalbuminuria is the earliest clinical manifestation of CKD in type 2 diabetes and persistent microalbuminuria represents an early clinical marker for the development of diabetic nephropathy (DN)⁷⁷. Although the number of studies exploring the epidemiology of microalbuminuria across Asia has been limited, the Microalbuminuria Prevalence Study (MAPS) of 6,800 hypertensive diabetic patients from 10 countries in the region reported an overall prevalence rate of 39.8% (95% confidence interval [CI] 39.2–40.5)²². The prevalence in individual countries across Southeast Asia is given in Table 1. These data show how a high proportion of hypertensive, type 2 diabetes Asian patients are showing early signs of declining renal function, and further support a need for early intervention so as to reduce accelerated progression of cardio-renal complications and the associated healthcare burden²⁶–³¹.

In recognition of the utility of measuring microalbuminuria, guidelines recommend annual screening of this clinical marker for identifying at-risk populations⁸. Patients identified with microalbuminuria early in the course of disease might require stricter glycemic and blood pressure control targets. Indeed, several prospective studies have shown the importance of tight glycemic control alone and combined with blood pressure lowering in the prevention of microvascular complications. For instance, the UK Prospective Diabetes Study compared the effects of intensive blood-glucose control with either sulfonylureas or insulin resulted in a 33% relative risk reduction in type 2 diabetes patients after treatment with either intensive glycemic control (HbA1c ≤ 6.5%) or standard glucose control (defined by local guidelines) with placebo or ACEI plus indapamide therapy. A combination of intensive glucose control plus ACEI plus indapamide therapy led to a significant percentage in risk reduction in new or worsening nephropathy (95% CI 12–50%; P = 0.005); a 54% reduction in the development of new-onset microalbuminuria (95% CI 35–68%; P < 0.001), and a 25% reduction in the risk of new-onset microalbuminuria (95% CI 16–33%; P < 0.001). Furthermore, the effects of blood pressure lowering and intensive glucose control were independent of each other, so that on combining these agents, additive benefits were observed, particularly on renal outcomes³⁸.

In the Kumamoto study, the frequency and severity of diabetic microvascular complications were assessed in Japanese type 2 diabetes patients after treatment with either intensive glucose control (multiple insulin injections of three or more) or conventional therapy (insulin injections administered once or twice daily). There was a significant reduction in the progression of nephropathy and other microvascular complications (retinopathy) after intensive insulin therapy (P < 0.05)³⁵.

The effect of an intensive, step-wise multifactorial intervention, targeting hyperglycemia, hypertension, dyslipidemia and microalbuminuria, on the initiation and progression of microvascular complications in type 2 diabetes patients with microalbuminuria was assessed in the Steno-2 study. Type 2 diabetes patients receiving early intensive diabetes management including tight glucose control and angiotensin converting enzyme inhibitors (ACEI) to reduce blood pressure were significantly less likely to develop nephropathy than patients receiving standard therapy (odds ratio 0.27; 95% CI 0.10–0.75). This reduction in risk was maintained in an observational follow up of 5.5 years³⁶–³⁷.

In the most recent analysis of the Action in Diabetes and Vascular disease: preterAx and diamicron-modified release Controlled Evaluation (ADVANCE) trial, which included a large number of Asian type 2 diabetes patients, further support for the benefits of combining blood-pressure lowering with intensive blood glucose control was provided³⁸. Patients received either intensive glucose control (target glycated hemoglobin [HbA1c] ≤ 6.5%) or standard glucose control (defined by local guidelines) with placebo or ACEI plus indapamide therapy. A combination of intensive glucose control plus ACEI plus indapamide therapy led to a significant percentage in risk reduction in new or worsening nephropathy (95% CI 12–50%; P = 0.005); a 54% reduction in the development of new-onset microalbuminuria (95% CI 35–68%; P < 0.001), and a 25% reduction in the risk of new-onset microalbuminuria (95% CI 16–33%; P < 0.001). Furthermore, the effects of blood pressure lowering and intensive glucose control were independent of each other, so that on combining these agents, additive benefits were observed, particularly on renal outcomes³⁸.

Indeed, the benefits of early and tight target control strategies on the prevention of DN in Chinese type 2 diabetes patients have been observed. In this Asian cohort with normoalbuminuria, achievement of American Diabetes Association (ADA)-recommended targets of HbA1c (<7%), systolic blood pressure (<130 mmHg), diastolic blood pressure (<80 mmHg) and lipid profiles (low-density lipoprotein [LDL] <100 mg/dL; triglycerides <150 mg/dL; high-density lipoprotein >40–50 mg/dL) reduced the risk of developing new-onset microalbuminuria compared with those who were unable to attain these targets³⁹. Interestingly, in a separate study of Taiwanese type 2 diabetes patients with microalbuminuria, almost 36% of patients achieved remission to normoalbuminuria following a tight, multifactorial target control approach⁴⁰.

### Table 1 | Prevalence of microalbuminuria in selected countries across Southeast Asia

| Country       | Prevalence of microalbuminuria (%) |
|---------------|-----------------------------------|
| Hong Kong     | 24.9                              |
| Indonesia     | 33.0                              |
| Malaysia      | 39.7                              |
| Singapore     | 48.5                              |
| Taiwan        | 26.9                              |
| Thailand      | 43.3                              |

With the exception of Taiwan (Chiang SC et al. JCMA 2011; 74: 3–10), these data are based on subanalyses of the Microalbuminuria Prevalence Study of 6,800 hypertensive diabetic patients from 10 countries across Asia (Wu AY et al. Diabetologia 2005; 48: 17–26).
Impact of CKD in Type 2 Diabetes

Worldwide, rates of CKD have been increasing, and have accompanied the increasing prevalence of type 2 diabetes, hypertension and CVD. For instance, in the USA, it is estimated that 30% of patients with type 2 diabetes will develop some form of kidney disease as reflected by protein leakage, microalbuminuria, macroalbuminuria or a decline in the glomerular filtration rate (GFR)\textsuperscript{43}. Indeed, incidence rates of ESRD across Asia have shown increases over a 6-year period (2003–2008) of 15.8% in Hong Kong, 22% in Malaysia and Thailand, 24% in Singapore, and up to 31% in the Philippines\textsuperscript{40,44}. Although incidence rates of ESRD appear to have declined in Taiwan since 2005, this country has the third highest rate of ESRD in the world, with an incidence rate of 384 per million population (pmp), highlighting the disparity between the rate of kidney disease and a country’s economic status\textsuperscript{42}. Furthermore, it has become apparent that a high proportion of ESRD cases are as a result of diabetes, ranging from 41% to 62% in individual countries across Southeast Asia (Figure 2)\textsuperscript{43,44}.

Morbidity and mortality associated with CKD itself is enormous. The presence of CKD is also associated with a high CVD risk, which is further exacerbated by the presence of diabetes and hypertension\textsuperscript{45}. Indeed, CVD remains the main cause of death in patients with CKD rather than kidney failure, and it is estimated that CVD-associated mortality is 10–30-fold higher in patients with advanced CKD receiving dialysis than the general population\textsuperscript{46}. Given that the prevalence of hypertension in Asia is increasing, and that diabetes and hypertension commonly coexist (type 2 diabetes patients are twice as likely to have elevated blood pressure than non-type 2 diabetes patients), screening these high-risk patients for CKD early might help slow the course of renal function decline and reduce the greater cardiovascular mortality risk observed in such individuals\textsuperscript{47–49}.

**IMPACT OF DECLINING RENAL FUNCTION ON TYPE 2 DIABETES CONTROL**

Despite the advent and availability of a range of antidiabetic and blood pressure lowering agents, many patients in Asia remain suboptimally controlled and therefore at risk of developing complications. In the MAPS study, just 10.6% of type 2 diabetes Asian patients with microalbuminuria achieved blood pressure targets below 130/80 mmHg and mean HbA\textsubscript{1c} levels of 7.9%\textsuperscript{22}. Similarly, in a cross-sectional survey in China, the majority of type 2 diabetes patients with nephropathy (66.9%) had a mean HbA\textsubscript{1c} level of >7.5%, indicating poor glycemic control in patients with complications\textsuperscript{48}. These data are supported by the recent International Diabetes Management Practice Study (IDMPS) that explored the barriers to achieving optimal glycemic control across Asia, Latin America and Eastern Europe\textsuperscript{51}. In Asia, of the 5,372 type 2 diabetes patients assessed, 35.8% had microalbuminuria and just 37.3% achieved the HbA\textsubscript{1c} target of <7.0%; 21.8% achieved the blood pressure target of <130/80 mmHg; and 37% achieved the LDL cholesterol target of <100 mg/dL. Another significant and worrying finding was that just 4.7% of patients in Asia attained all three treatment targets\textsuperscript{51}.

Factors that might be contributing to such low control rates have been reported to include: difficult medical access by patients in some developing countries, physician perception of target levels, prescribing habits, as well as knowledge of guidelines – these findings highlight a discord between evidence and practice\textsuperscript{22,51}. An aging population provides additional challenges in managing type 2 diabetes, as aging itself is associated with changes in kidney structure and function, and these age-related renal changes can be accelerated by the presence of comorbid conditions\textsuperscript{52,53}. Furthermore, a study of the Hong Kong Diabetes Registry revealed how long disease duration and complexity of treatment regimens might also play a role in suboptimal glycemic control\textsuperscript{54}. Poor control might also result in type 2 diabetes patients who present and commence treatment when their renal function is normal, but subsequently go on to develop kidney disease. Without appropriate monitoring of GFR levels and diagnosis of kidney disease or its progression, the need for dose adjustments or re-evaluation of prescribed therapies might be missed and, consequently, adverse side-effects might arise\textsuperscript{55}.

Hypoglycemia is a particular challenge in the management of type 2 diabetes, especially in patients with a decline in renal function. For instance, diabetic patients with CKD are twice as likely to experience hypoglycemic events than those without kidney disease\textsuperscript{56}. This might be a result of reduced insulin clearance, reduced gluconeogenesis by the kidney and increased

![](figure2.png)

**Figure 2** | Incidence of end-stage renal disease (ESRD) as a result of diabetes in selected countries across Southeast Asia in 2008. These data are based on figures compiled by the US Renal Disease System (Figure adapted from 2010 US Renal Disease System Annual Report Chapter 12 International Comparisons; volume 2; pages 383–396). For Singapore, the 2008 data have been extracted from the National Registry of Diseases Office, Released 1 March 2011 (NP-11-1).
accumulation of drugs excreted by the kidney. The reduction in drug clearance results in prolonged exposure to the drug itself or its metabolites, which can lead to adverse side-effects. This is a major issue in moderate to severe CKD (stages 3–5) when renal dysfunction is particularly pronounced.

CURRENT ORAL ANTI-DIABETICS IN DIABETIC PATIENTS WITH CKD

The American Diabetes Association guidelines recommend target HbA1c levels of <8% for patients with more advanced microvascular complications and increased risk of hypoglycemia, such as those with more advanced CKD. However, in practice, the use of antidiabetic medications in achieving these glycemic targets is often challenging.

There are now an array of anti-hyperglycemic agents available that include both injectable, such as insulin and the incretin mimetics – GLP-1 analogs (exenatide, liraglutide), and oral antidiabetics (OADs). Among the OADs are biguanides (metformin), second generation sulfonylureas (glimepiride, glipizide, gliclazide), meglitinides (nateglinide, repaglinide), α-glucosidase inhibitors (acarbose), thiazolidinediones (TZD; pioglitazone) and incretin-based therapies that include dipeptidyl-peptidase IV (DPP-4) inhibitors (linagliptin, sitagliptin, vildagliptin, saxagliptin). In addition, oral sodium-glucose transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin). Despite the range of medications available for the treatment of type 2 diabetes and its complications, many of these require dose modification or avoidance and close monitoring.

This poses a particular challenge in more advanced disease (CKD stages 3–5), where contraindications or the increased risk of hypoglycemia serve to limit the number of treatment options. This is compounded in patients with advanced renal dysfunction.

As all these agents differ in their mechanism of action, efficacy, side-effects and costs, the choice of therapy should be guided by several factors. Patient demographics, presence of comorbid conditions, risk or severity of renal function decline, tolerability, and risk of developing adverse events, such as hypoglycemia, weight gain and edema, should help in the treatment decision process.

With most of the OADs currently available for the treatment of type 2 diabetes, their use in patients with kidney dysfunction is compromised. Sulfonylureas are one of most commonly prescribed oral antihyperglycemic agents in Southeast Asia. However, sulfonylureas and their metabolites are affected by kidney function by increasing in potency as renal function declines. Furthermore, in type 2 diabetes patients with ESRD receiving dialysis, treatment with sulfonylureas might lead to severe and prolonged episodes of hypoglycemia.

Consequently, sulfonylureas are contraindicated in patients with advanced CKD. However, second-generation sulfonylureas, such as gliclazide and glipizide, which have inactive metabolites, carry less risk of hypoglycemia than the first-generation sulfonylureas and might therefore be used in type 2 diabetes patients with declining renal function, but with caution.

Similarly, the meglitinide, nateglinide, undergoes hepatic metabolism that gives rise to weakly active metabolites that are excreted predominantly through the kidneys. Furthermore, 15% of the drug is excreted unchanged in urine. Given the reduced clearance in CKD and the likelihood of hypoglycemic episodes, cautious use in these special populations, particularly in more advanced stages of CKD, is warranted. In contrast, repaglinide appears to have a lower risk of hypoglycemia and might be of use in CKD stages 3 and 4, but requires low initial dosing and careful dose titration in these patients.

The use of metformin, the standard first-line therapy of type 2 diabetes, also poses a risk for diabetic patients with CKD as a result of lactic acidosis, and is therefore contraindicated in patients with advanced renal dysfunction. Whether this medication provides an additional risk to the underlying comorbidity or acts directly to bring about lactic acidosis requires further investigation.

Treatment with α-glucosidase inhibitors in type 2 diabetes patients with CKD (stage 3–5) is associated with a higher risk of hypoglycemia, weight gain and edema, should help in the treatment decision process.
also not recommended, because of the potential risk of hepatic damage as a result of cumulated dose effects.

In contrast, a few small, short-term studies have implicated a renoprotective role for TZD, as it resulted in greater reductions in albuminuria than metformin or sulfonylureas. Whether this translates into direct prevention of renal function decline, however, requires further study. Nevertheless, TZD undergo hepatic metabolism and have a low risk of hypoglycemia, making them appropriate for use in CKD. Of note, fluid retention is a known side-effect of TZD, and in CKD patients this outcome could be exacerbated.

DPP-4 inhibitors are the most recent addition to the type 2 diabetes treatment paradigm and have been developed in recognition of the multifactorial nature of type 2 diabetes pathology. This drug class mediates its antihyperglycemic effects by preventing the degradation of the incretin hormones – glucagon-like peptide (GLP)-1 and glucose-dependent insulino-tropic peptide (GIP). These hormones are released in the intestine after a meal, and target the pancreas by increasing glucose-dependent insulin secretion and suppressing glucagon secretion, which subsequently improves both fasting plasma glucose (FPG) and post-prandial glucose (PPG) levels. DPP-4 inhibitors are therefore important in regulating glucose homeostasis. Furthermore, beneficial effects on pancreatic β-cells have also been reported with this drug class and therefore it might play a role in preventing or slowing the progression of β-cell dysfunction.

There are currently five DPP-4 inhibitors approved for type 2 diabetes: sitagliptin, vildagliptin, saxagliptin, alogliptin (Japan) and linagliptin; and their efficacy and tolerability have been studied in several clinical trials. Although there are limited direct head-to-head studies between DPP-4 inhibitors that have been carried out to date, observations across studies suggest that all five agents have comparable efficacy as reflected in their levels of HbA1c reduction. This is in line with their similar inhibitory potentials. When compared with other antihyperglycemic agents, head-to-head studies showed DPP-4 inhibitors to have similar efficacy to metformin, sulfonylureas, TZD and α-glycosidase inhibitors. In terms of tolerability, all five DPP-4 inhibitors have been shown to be well tolerated with low rates of adverse effects and, in general, comparable with placebo or comparator. Furthermore, the issues of hypoglycemia and weight gain seen with the more traditional antihyperglycemic therapies are not readily observed with DPP-4 inhibitors.

Although there is little to differentiate between these agents in terms of observed efficacy, each differs in their chemistry and pharmacokinetic profile, which might translate into differences in their clinical applicability. Indeed, DPP-4 inhibitors differ in their half-lives: sitagliptin, alogliptin and linagliptin have long-half lives, allowing for once-daily administration; vildagliptin has a short half-life and twice-daily dosing is recommended. Saxagliptin has a short half-life, but given its active metabolite, once-daily dosing is adequate. Furthermore, on examining their metabolism and excretion profiles, differences between the DPP-4 inhibitors have emerged. Sitagliptin, vildagliptin, alogliptin and saxagliptin are predominately excreted through the kidneys. Despite the renal excretion profiles of these agents, their favorable tolerability in patients with various severity of renal dysfunction still permits their use in such patients, although dose modifications are recommended in line with increasing kidney dysfunction. In contrast, linagliptin is excreted through the bile and with approximately 5% being renally excreted. Furthermore, recent data suggest that dose modifications of linagliptin are not required irrespective of the severity of renal dysfunction. Linagliptin might therefore represent an important addition to the currently limited therapeutic armamentarium for achieving glycemic control in type 2 diabetes patients with declining renal function.

In recognition of the favorable clinical profile of DPP-4 inhibitors, recent international guidelines recommend DPP-4 inhibitors as an option in both first-line (when FPG and PPG levels are elevated) and combination therapy. Thus, type 2 diabetes patients, particularly special populations like those who are renally impaired, benefit from the emergence and evolution of newer antidiabetic agents, such as the DPP-4 inhibitors, that address the limitations of older therapies, and allow for a more tailored and effective approach to disease control. Long-term studies to assess the impact of DPP-4 inhibitors on reducing the risk of diabetes complications are awaited.

CONCLUSIONS
The burden of type 2 diabetes and its complications across Southeast Asia continues. DPP-4 inhibitors represent a good choice of OAD for patients with type 2 diabetes. Within this drug class, linagliptin, a novel DPP-4 inhibitor, possesses favorable and comparable profiles in terms of both efficacy and adverse events, and is indicated for use in all patients with type 2 diabetes.

Furthermore, linagliptin is the only DPP-4 inhibitor that is not predominantly dependent on renal metabolism. Many antidiabetic therapies are often of little use in renally-impaired type 2 diabetes patients because of contraindications or increased risk of hypoglycemia. The favorable pharmacokinetic profile of linagliptin has advantageous implications given the importance of addressing the decline in renal function in Asian patients with type 2 diabetes early. In addition, the lack of dose modification requirements and ease of dosing (one dose, once daily) further support the suitability of linagliptin in these difficult-to-treat populations.

ACKNOWLEDGEMENTS
Editorial support was provided by Dr Beejal Vyas-Price and Mr Cheuk Lee from Complete Medical Group, and was paid for by Boehringer Ingelheim. The authors declare the following financial relationships: FCCC has received honoraria for lecturing and membership in advisory boards for Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck.

© 2012 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd
Sharpe and Dohme, Novo Nordisk and Takeda. SPC has received honoraria for lecturing for Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, Merck Sharpe and Dohme, Novartis, Novo Nordisk, and Sanofi-Aventis; and is a member of regional and local advisory boards for Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharpe and Dohme, and Novo Nordisk. CMH has received consulting and/or speaker fees from Pfizer, Merck, Bayer, AstraZeneca and Abbott Laboratories, and research funds from Merck, AstraZeneca, Pfizer and Sanofi. SS has not declared any financial relationships. AYTW is a member of the regional linagliptin advisory board and received honoraria from Boehringer Ingelheim for lecturing. SYG received honorarium from Boehringer Ingelheim as an advisory board member for linagliptin, and is also an advisory board member for Merck, Inc and Novo Nordisk. MBZ received an honorarium from Boehringer Ingelheim Philippines as an Advisory Board member for linagliptin.

REFERENCES

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27: 1047–1053.

2. International Diabetes Federation. Foreword Available at: http://www.diabetesatlas.org/content/foreword-0 (accessed 30 May 2011).

3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. *JAMA* 2009; 301: 2129–2140.

4. World Health Organization. Noncommunicable Diseases. Available at: http://www.searo.who.int/en/Section1174/Section1459_7409.htm (accessed 2 July 2011).

5. Wong KC, Whang Z. Prevalence of Type 2 diabetes mellitus of Chinese populations in mainland China, Hong Kong, and Taiwan. *Diabetes Res Clin Pract* 2006; 73: 126–134.

6. Leung G, Lam K. Diabetic complications and their implications on health care in Asia. *Hong Kong Med J* 2000; 6: 61–68.

7. Fowler M. Microvascular and macrovascular complications of diabetes. *Clin Diabetes* 2008; 26: 77–82.

8. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001; 414: 782–787.

9. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. *Diabetes Care* 2003; 26: 360–366.

10. Economic Impact of Diabetes. IDF Diabetes Atlas Fourth Edition. Available at: http://www.diabetesatlas.org/content/economic-impacts-diabetes (accessed 4 June 2011).

11. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. *N Engl J Med* 2010; 362: 1090–1100.

12. Lin T, Chou P, Lai MS, et al. Direct costs-of-illness of patients with diabetes mellitus in Taiwan. *Diabetes Res Clin Pract* 2001; 54(Suppl 1): S43–S46.

13. Chan BSW, Tsang MW, Lee WW, et al. Cost of type 2 diabetes mellitus in Hong Kong Chinese. *Int J Clin Pharmacol Ther* 2007; 45: 455–468.

14. Goldhaber-Fiebert JD, Li H, Ratanawijitrasin S, et al. Inpatient treatment of diabetic patients in Asia: evidence from India, China, Thailand and Malaysia. *Diabetes Metab* 2010; 27: 101–108.

15. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. *Lancet* 2006; 368: 1681–1688.

16. Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. *Diabetes Care* 1995; 18: 747–753.

17. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. *Diabetes Care* 1997; 20: 1562–1568.

18. Yajnik CS. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. *J Nutr* 2004; 134: 205–210.

19. Radha V, Mohan V. Genetic predisposition to type 2 diabetes among Asian Indians. *Indian J Med Res* 2007; 125: 259–274.

20. Toh MPH, Wu CX, Leong HSS, et al. Association of younger age with poor glycemic and cholesterol control in Asians with type 2 diabetes mellitus in Singapore. *J Endocrinol Metab* 2011; 1: 27–37.

21. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific Region. *Diabetes Care* 2003; 26: 360–366.

22. Ku Y, Kong NC, de Leon FA, et al. An alarming high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) study. *Diabetologia* 2005; 48: 17–26.

23. Luk A, Chan JCN. Diabetic nephropathy – what are the unmet needs? *Diabetes Res Clin Pract* 2008; 82: S15–S20.

24. K/DOQIWork Group. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. *Am J Kidney Dis* 2002; 39: s46–s75.

25. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011; 80: 17–28.

26. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a Southeast Asian population: a 12-year cohort study. *J Am Soc Nephrol* 2005; 16: 791–799.

27. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 1984; 310: 356–360.

28. Yeung VT, LeeKF, Chan SH, et al. Microalbuminuria Prevalence Study (MAPS) in hypertensive type 2 diabetic
patients in Hong Kong. *Hong Kong Med J* 2006; 12: 185–190.

29. Sia'bani M, Asdie AH, Widayati K, et al. Microalbuminuria prevalence study in hypertensive patients with type 2 diabetes in Indonesia. *Acta Med Indones* 2005; 37: 199–204.

30. Kong N, Chia YC, Khalid BA, et al. Microalbuminuria prevalence study in hypertensive type 2 diabetic patients in Malaysia. *Med J Malaysia* 2006; 61: 457–465.

31. Buranakitjaroen P, Deerochanawong C, Bunnag P. Microalbuminuria prevalence study (MAPS) in hypertensive patients with type 2 diabetes in Thailand. *J Med Assoc Thai* 2005; 88: 1624–1629.

32. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; 32: 193–203.

33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPD) Group. *Lancet* 1998; 352: 837–853.

34. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; 359: 1577–1589.

35. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000; 23(Suppl 2): B21–B29.

36. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 1999; 353: 617–622.

37. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008; 358: 580–591.

38. Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. *Diabetes Care* 2009; 32: 2068–2074.

39. Tu ST, Chang SJ, Chen JF, et al. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus. *Arch Intern Med* 2010; 170: 155–161.

40. Hseih MC, Hseih YT, Cho TJ, et al. Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control. *Eur J Clin Invest* 2011; 41: 870–878.

41. Dalla Vestra M, Saller A, Bortoloso E. Structural involvement in type 1 and type 2 diabetic nephropathy. *Diabetes Metab* 2000; 26(Suppl 4): 8–14.

42. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. *JAMA* 2002; 287: 2519–2527.

43. US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.

44. Singapore Health Promotion Board. Information Paper on End-Stage Renal Disease. March 2011. National Registry of Diseases Office. Available at: http://www.nrdo.gov.sg/

45. Bakris G, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. *J Clin Hypertens (Greenwich)* 2009; 11: 144–147.

46. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. *Circulation* 2003; 108: 2154–2169.

47. Levey AS, Astor BC, Stevens LA, et al. Chronic kidney disease, diabetes, and hypertension: what’s in a name? *Kidney Int* 2010; 78: 19–22.

48. Epstein M, Sowers JR. Diabetes mellitus and hypertension. *Hypertension* 1992; 19: 403–418.

49. Stamer J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. *Diabetes Care* 1993; 46: 434–444.

50. Liu Z, Fu C, Wang W, et al. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients—a cross-sectional hospital based survey in urban China. *Health Qual Life Outcomes* 2010; 8: 62.

51. Chan JC, Malik V, Ija W, et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. *Diabetes Care* 2009; 32: 227–233.

52. Linderman RD. Is the decline in renal function with normal aging inevitable? *Kidney Int* 1984; 26: 861–868.

53. Ribstein J, Du Callar G, Mlrmam A. Glucose tolerance and age-associated decline in renal function of hypertensive patients. *J Hypertens* 2001; 19: 2257–2264.

54. Tong PCY, Ko GTC, So WY, et al. Use of anti-diabetic drugs and glycemic control in type 2 diabetes—the Hong Kong Diabetes Registry. *Diabetes Res Clin Pract* 2008; 82: 346–352.

55. Cavanaugh K. Diabetes management issues for patients with chronic kidney disease. *Clin Diabetes* 2007; 25: 90–97.

56. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. *Clin J Am Soc Nephrol* 2009; 4: 1121–1127.

57. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. *Am J Kidney Dis* 2007; 2: 512–5154.

58. American Diabetes Association. Clinical practice guidelines. *Diabetes Care* 2012; 35: 511–563.
59. Zelmanovitz T, Gerchman F, Balthazar AP, et al. Diabetic nephropathy. *Diabetol Metab Syndr* 2009; Sep 21; 1: 10.
60. International Diabetes Federation. Diabetes Atlas, 3rd edn. International Diabetes Federation, Brussels, 2006.
61. Krepsinsky J, Ingram AJ, Classe CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. *Am J Kidney Dis* 2000; 35: 500–505.
62. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. *Am J Kidney Dis* 2007; Nov; 50: 865–879.
63. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007; 147: 386–399.
64. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. *J Hum Hypertens* 2003; 17: 7–12.
65. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. *Diabetes Care* 1998; 21: 2135–2139.
66. Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. *Diabet Med* 2001; 18: 308–313.
67. Thomas L, Tadayon M, Mark M, et al. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. *J Pharmacol Exp Ther* 2009; 328: 556–563.
68. Khoo J, Rayner CK, Jones KL, et al. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. *Ther Clin Risk Manag* 2009; 5: 683–698.
69. Ahren B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. *Horm Metab Res* 2007; 39: 826–829.
70. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. *Diabetes Care* 2005; 28: 1936–1940.
71. Henry R, Smith S, Schwartz S, et al. β-cell stimulation by saxagliptin in patients with T2D [abstract no. 447-P plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5–9; New Orleans (LA)
72. Deacon C. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. *Diabetes Obes Metab* 2011; 13: 7–18.
73. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. *Diabetes Obes Metab* 2010; 12: 252–261.
74. Schweizer A, Dejager S, Bosi E, et al. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Obes Metab* 2009; 11: 804–812.
75. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2010; 11: 157–166.
76. Nauck A, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab* 2007; 9: 194–205.
77. Bolli G, Dotta F, Rochette E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab* 2010; 10: 82–90.
78. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2010; 10: 959–969.
79. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. *Diabetes Obes Metab* 2010; 12: 648–658.
80. Blech J, Ludwig-Schwelling ER, Grafe-Mody EU, et al. The metabolism and disposition of oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. *Drug Metab Dispos* 2010; 38: 667–678.
81. Hesse T, Grafe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. *Diabetes Obes Metab* 2009; 11: 786–794.
82. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract* 2009; 15: 541–559.